首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.
【24h】

Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.

机译:基于微阵列的CUB结构域蛋白1作为常规肾细胞癌的潜在预后标志物的鉴定。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Renal cell carcinoma (RCC) is characterized by a variable and unpredictable clinical course. Thus, accurate prediction of the prognosis is important in clinical settings. We conducted microarray-based study to identify a novel prognostic marker in conventional RCC. PATIENTS AND METHODS: The present study included the patients surgically treated at Kyoto University Hospital. Gene expression profiling of 39 samples was carried out to select candidate prognostic markers. Quantitative real-time PCR of 65 samples confirmed the microarray experiment results. Finally, we evaluated the significance of potential markers at their protein expression level by immunohistochemically analyzing 230 conventional RCC patients. RESULTS: Using expression profiling analysis, we identified 14 candidate genes whose expression levels predicted unfavorable disease-specific survival. Next, we examined the expression levels of nine candidate genes by quantitative real-time PCR and selected CUB-domain containing protein 1 (CDCP1) for further immunohistochemical analysis. Positive staining for CDCP1 inversely correlated with disease-specific and recurrence-free survivals. In multivariate analysis including clinical/pathological factors, CDCP1 staining was a significant predictor of disease-specific and recurrence-free survivals. CONCLUSIONS: We identified CDCP1 as a potential prognostic marker for conventional RCC. Further studies might be required to confirm the prognostic value of CDCP1 and to understand its function in RCC progression.
机译:目的:肾细胞癌(RCC)的特点是临床过程多变且不可预测。因此,在临床环境中准确预测预后很重要。我们进行了基于微阵列的研究,以鉴定常规RCC中的新型预后标志物。病人和方法:本研究包括在京都大学医院手术治疗的患者。进行39个样品的基因表达谱分析,以选择候选的预后标志物。 65个样品的实时定量PCR证实了微阵列实验结果。最后,我们通过免疫组织化学分析230例常规RCC患者,评估了潜在标志物在其蛋白表达水平上的意义。结果:使用表达谱分析,我们鉴定了14个候选基因,这些基因的表达水平预测了疾病特异性的存活率。接下来,我们通过定量实时PCR检查了9个候选基因的表达水平,并选择了包含CUB域的蛋白1(CDCP1)进行进一步的免疫组织化学分析。 CDCP1的阳性染色与疾病特异性和无复发生存率呈负相关。在包括临床/病理因素在内的多变量分析中,CDCP1染色是疾病特异性和无复发生存的重要预测指标。结论:我们将CDCP1鉴定为常规RCC的潜在预后标志物。可能需要进一步的研究来确认CDCP1的预后价值,并了解其在RCC进展中的功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号